# Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study

> **NCT06785584** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Fujian Medical University Union Hospital** · enrollment: 30 (estimated)

## Conditions studied

- ALK-positive Advanced NSCLC
- ALK-positive Non-small Cell Lung Cancer (NSCLC)
- MPR
- Neoadjuvant Therapy

## Interventions

- **DRUG:** Ensartinib

## Key facts

- **NCT ID:** NCT06785584
- **Lead sponsor:** Fujian Medical University Union Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-02-01
- **Primary completion:** 2025-12-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06785584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06785584, "Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06785584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*